Bill to cut red tape for new meds in Australia stalled by delay

A bill to enable regulatory reform measures in Australia stemming from the review of Medicines and Medical Devices Regulation (MMDR) has been delayed.

The Therapeutic Goods Amendment (2016 Measures No 1) Bill 2016 has been referred to the Senate Community Affairs Legislation Committee for inquiry and report.

Trade group AusBiotech is a supporter of the MMDR’s regulatory reforms and efforts to reduce costs and administrative burden for industry, as they seek to make the assessment process shorter and simpler, while promising to maintain the safety and quality of medicines and medical devices.